![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB |
Preview |
PDF (Supplemental Data)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
437kB |
| Item Type: | Article |
|---|---|
| Title: | Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study |
| Creators: |
Shumilov, E.  ORCID: https://orcid.org/0000-0003-0178-1729, Wurm-Kuczera, R., Kerkhoff, A. ORCID: https://orcid.org/0000-0001-6904-2821, Wang, M. ORCID: https://orcid.org/0009-0006-1426-4594, Melchardt, T. ORCID: https://orcid.org/0000-0002-0122-3631, Holtick, U. ORCID: https://orcid.org/0000-0002-5543-0257, Bacher, U. ORCID: https://orcid.org/0000-0001-8771-947X, Staber, P.B. ORCID: https://orcid.org/0000-0001-6729-7708, Mazzeo, P. ORCID: https://orcid.org/0000-0001-6317-0216, Leng, C. ORCID: https://orcid.org/0009-0006-4007-9122, Böckle, D. ORCID: https://orcid.org/0000-0002-1783-9641, Hölscher, A.S. ORCID: https://orcid.org/0009-0004-8994-1137, Kauer, J. ORCID: https://orcid.org/0000-0003-1632-0167, Rotter, N. ORCID: https://orcid.org/0009-0009-9813-5344, Vucinic, V. ORCID: https://orcid.org/0000-0002-8398-285X, Rudzki, J.D. ORCID: https://orcid.org/0000-0001-7963-3385, Nachbaur, D. ORCID: https://orcid.org/0009-0006-6243-915X, Bücklein, V.L. ORCID: https://orcid.org/0000-0001-7391-7280, Schnetzke, U. ORCID: https://orcid.org/0000-0001-7455-8988, Krämer, I. ORCID: https://orcid.org/0000-0003-1667-4109, Wille, K. ORCID: https://orcid.org/0000-0002-7682-8563, Hasse, A., von Tresckow, B. ORCID: https://orcid.org/0000-0003-1410-4487, Hänel, M. ORCID: https://orcid.org/0000-0002-4767-3275, Koenecke, C. ORCID: https://orcid.org/0000-0001-7025-1735, Velazquez, G.F. ORCID: https://orcid.org/0000-0003-2884-3432, Viardot, A. ORCID: https://orcid.org/0000-0001-9593-6327, Schmid, C. ORCID: https://orcid.org/0000-0001-7070-487X, Thurner, L. ORCID: https://orcid.org/0000-0002-8167-2989, Wolf, D. ORCID: https://orcid.org/0000-0002-4761-075X, Subklewe, M. ORCID: https://orcid.org/0000-0003-3905-0251, Dreyling, M. ORCID: https://orcid.org/0000-0002-0358-5249, Dreger, P. ORCID: https://orcid.org/0000-0002-7429-8570, Dietrich, S. ORCID: https://orcid.org/0000-0002-0648-1832, Keller, U. ORCID: https://orcid.org/0000-0002-8485-1958, Jäger, U. ORCID: https://orcid.org/0000-0001-9826-1062, Greil, R. ORCID: https://orcid.org/0000-0002-4462-3694, Pabst, T. ORCID: https://orcid.org/0000-0002-6055-5257, Lenz, G. ORCID: https://orcid.org/0000-0002-4728-1693 and Chapuy, B. ORCID: https://orcid.org/0000-0002-6485-8773
|
| Abstract: | Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes of 70 patients with r/r DLBCL treated with glofitamab as part of the compassionate use patient program in Germany, Austria, and Switzerland. The median number of prior treatment lines was 4, with 71% of patients refractory to their last treatment. Cytokine release syndrome was observed in 40% of patients (grade 3-4 in 2%), immune effector cell–associated neurotoxicity syndrome in 10% (grade 3 in 1%), and infections in 31% (grade 5 in 3%). The overall response rate was 46%, with 27% achieving complete responses (CR) and 19% partial responses. The median progression-free survival (PFS) was 3.6 months, whereas the median overall survival was 5.7 months. Notably, 13 patients (19%) were in CR 6 months after initiating glofitamab and exhibited durable responses. Elevated lactate dehydrogenase is the most robust predictor of inferior outcome. Patients pretreated with bendamustine within 6 months prior to glofitamab initiation exhibited significantly reduced PFS, suggesting that bendamustine may impair T-cell fitness and hence glofitamab efficacy. In summary, glofitamab demonstrates promising efficacy and a manageable safety profile in heavily pretreated patients with r/r DLBCL in a real-world scenario and the optimal sequence of treatments should use T-cell–depleting agents before glofitamab with caution. |
| Keywords: | Bispecific Antibodies, Diffuse Large B-Cell Lymphoma, Immunological Antineoplastic Agents, Recurrence, Retrospective Studies, Treatment Outcome |
| Source: | Blood Advances |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Volume: | 9 |
| Number: | 15 |
| Page Range: | 3865-3877 |
| Date: | 12 August 2025 |
| Official Publication: | https://doi.org/10.1182/bloodadvances.2024014903 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
